Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL714994 | 0.77 | CCR1 (0.56) | TGFBR1MEN1RAB9AKMT2A | |
| SCHEMBL715045 | 0.77 | MEN1 (0.61) | MEN1RAB9AKMT2AHSD17B10 | |
| SCHEMBL29539234 | 0.73 | CCR1 (0.46) | TGFBR1MAPK14MEN1RAB9AKMT2A | |
| SCHEMBL229994 | 0.73 | CCR1 (0.46) | TGFBR1MAPK14MEN1RAB9AKMT2A | |
| SCHEMBL18422446 | 0.73 | CTSS (0.42) | — | |
| SCHEMBL31354842 | 0.71 | CCR1 (0.46) | TGFBR1MAPK14MEN1RAB9AKMT2A | |
| SCHEMBL700152 | 0.71 | CCR1 (0.46) | TGFBR1MAPK14MEN1RAB9AKMT2A | |
| SCHEMBL37815 | 0.69 | KDM4E (0.54) | RAB9AHSD17B10 | |
| SCHEMBL467101 | 0.69 | RAB9A (0.47) | MEN1RAB9AKMT2AHSD17B10 | |
| SCHEMBL3768 | 0.69 | MEN1 (0.68) | MEN1RAB9AKMT2AGABRA1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1248612-B1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-02-27 | — | — | EP | disclosed |
| EP-1248612-A4 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2005-09-07 | — | — | EP | disclosed |
| US-6525036-B2 | Treating post-menopausal osteoporosis. | MERCK & CO., INC. | 2003-02-25 | — | — | US | disclosed |
| EP-1248612-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2002-10-16 | — | — | EP | disclosed |
| WO-2002070519-A1 | MONOBACTAMS AS CATHEPSIN K INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| US-20020052378-A1 | Novel compounds and compositions as protease inhibitors | Celera Corporation | 2002-05-02 | — | — | US | disclosed |
| WO-2001049288-A9 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2001-10-25 | — | — | WO | disclosed |
| WO-2001049288-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2001-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052378-A1 | Novel compounds and compositions as protease inhibitors | SERPINB1, CTRL, SPINT2 | TGFBR1 2053/4885MAPK14 2604/4885MEN1 3729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.